Pharma Equity Group A/S (OCSE:PEG) Total Liabilities : kr46.52 Mil (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Total Liabilities?

Pharma Equity Group A/S's Total Liabilities for the quarter that ended in Mar. 2024 was kr46.52 Mil.

Pharma Equity Group A/S's quarterly Total Liabilities increased from Sep. 2023 (kr32.14 Mil) to Dec. 2023 (kr42.40 Mil) and increased from Dec. 2023 (kr42.40 Mil) to Mar. 2024 (kr46.52 Mil).

Pharma Equity Group A/S's annual Total Liabilities increased from Dec. 2021 (kr21.08 Mil) to Dec. 2022 (kr25.03 Mil) and increased from Dec. 2022 (kr25.03 Mil) to Dec. 2023 (kr42.40 Mil).

Pharma Equity Group A/S Total Liabilities Historical Data

The historical data trend for Pharma Equity Group A/S's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Total Liabilities Chart

Pharma Equity Group A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

13.68

23.30

21.08

25.03

42.40

Pharma Equity Group A/S Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															30.81	29.71	32.14	42.40	46.52

Pharma Equity Group A/S Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharma Equity Group A/S's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	34.332	+	(8.072	+	3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	42.40

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	81.335	-	38.931
	=	42.40

Pharma Equity Group A/S's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.504	+	(16.018	+	-0.0010000000000012
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	46.52

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	78.281	-	31.76
	=	46.52

Pharma Equity Group A/S Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group A/S (OCSE:PEG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.